LNSR

LENSAR Inc. (LNSR) | Rumor.io

LENSAR

LNSR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,275

Bullish sentiment (50-day avg)92%

Price to earnings ratio34.8

Market capitalization84.5M

Earnings per share0.2

Dividend yield (TTM)—

Revenue (annual)58.4M

Net income (annual)-34.3M

Social

What share of all stock conversation is about LNSR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

LENSAR, Inc. (LNSR) reported Q2 2026 results with revenue of $16.5M, up 18% YoY, and recurring revenue of $13.7M, up 20% YoY, making up 83% of total revenue.
The company swung to a profit in Q2 2026, with net income of $3.5M vs a $1.8M loss a year ago, and Adjusted EBITDA of $3.6M vs a $0.3M loss.
LNSR's stock price surged 28% after the strong Q2 results, with the market cap now around $99M, and the company's chart has become one of the most interesting on the screen.

Generated by AI

Sentiment

Of the messages about LNSR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.7% -9.35
Bearish	—	—	—	21.3% +9.35

Aug 13

LENSAR, Inc. has shown impressive Q2 results, with 18% YoY revenue growth and record profitability, breaking out of a slump and violently beating expectations.
The company's recurring revenue is high margin and growing, and it owns a quarter of the market, giving it a strong competitive position and patient capital.
LENSAR's operating expenses are plummeting, allowing for hockey stick profits, and its balance sheet is turning around with bigger cash generation around the corner, making it an attractive investment opportunity.

Generated by AI

Topics

Of the messages about LNSR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	69.84%
Technical Analysis	—	—	—	3.53%
Analysts	—	—	—	4.08%
Earnings	—	—	—	11.96%
Controversies	—	—	—	10.05%
Macro	—	—	—	0.54%

Mar 24

Alcon has agreed to acquire LENSAR, Inc. ($LNSR) for $14.00 per share in cash, with an additional $2.75 per share contingent on certain milestones.
The merger is subject to shareholder approval and is expected to be worth up to $430 million.
LENSAR shareholders are advised to vote against the deal, as the offer is considered grossly undervalued.

Generated by AI

Community

Of the messages about LNSR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.94%
Newcomers	—	—	—	67.06%

Aug 13

LENSAR, Inc. (LNSR) reported Q2 2026 earnings with a 18% YoY revenue growth and record profitability, with recurring revenue accounting for 83% of total revenue.
The company's Q2 results showed a significant improvement in its financial performance, with a net income of $3.5M and an Adjusted EBITDA of $3.6M, compared to a loss of $1.8M in the same period last year.
LENSAR's Q2 2026 earnings were seen as a positive surprise, with the stock surging 28% after the report, and the company's chart becoming one of the most interesting on the screen, according to market participants.

Generated by AI

News

Lake Street Keeps Their Buy Rating on LENSAR (LNSR)

Detailed price information for Lensar Inc (LNSR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Lensar Inc Earnings Call Highlights Growth Momentum

Detailed price information for Lensar Inc (LNSR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

LENSAR (LNSR) Q2 2026 Earnings Call Transcript

Detailed price information for Lensar Inc (LNSR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge

LENSAR Inc (LNSR) posts 18% revenue growth and its strongest adjusted EBITDA to date, driven by a 20% jump in recurring revenue and expanding US market share.

1mo agoYahoo Finance

Why is LENSAR stock surging today?

1mo agoInvesting.com

Also Discussed

Investors talking about LNSR also mention

#	Name	Attention
1	JPMorgan Equity Focus ETFJPEF	0%0
2	Ribbon Communications Inc.RBBN	0%0
3	Zai Lab Limited ADRZLAB	0%0
4	Rallybio Corp.RLYB	0%0
5	Shengfeng Development Ltd.SFWL	0%0
6	Ascent Industries Co.ACNT	0%new
7	Seneca Foods Corp. Class A Common StockSENEA	0%0
8	PS International Group Ltd.PSIG	0%0
9	Block, Inc.XYZ	0%0
10	STAAR Surgical CompanySTAA	0%new

LENSAR Inc.

Healthcare
Medical Devices

LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management. Its current portfolio centers on the LENSAR Laser System and the ALLY Robotic Cataract Laser System, which combine imaging, planning, and laser-based treatment tools to support surgeons in refractive cataract procedures. The company’s systems are used to help manage key steps of surgery, including treatment planning, precision delivery, and workflow efficiency in clinical settings. LENSAR also provides related consumables, procedure licenses, training, installation, and maintenance services, making its offerings part of a broader surgical platform rather than standalone hardware. Headquartered in Orlando, Florida, LENSAR serves ophthalmic practices and surgical centers in the United States and international markets.

Website

Location

2800 Discovery Drive

Orlando, FL, 32826

United States

Social

What share of all stock conversation is about LNSR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 13

LENSAR, Inc. (LNSR) reported Q2 2026 results with revenue of $16.5M, up 18% YoY, and recurring revenue of $13.7M, up 20% YoY, making up 83% of total revenue.
The company swung to a profit in Q2 2026, with net income of $3.5M vs a $1.8M loss a year ago, and Adjusted EBITDA of $3.6M vs a $0.3M loss.
LNSR's stock price surged 28% after the strong Q2 results, with the market cap now around $99M, and the company's chart has become one of the most interesting on the screen.

Generated by AI

Sentiment

Of the messages about LNSR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.7% -9.35
Bearish	—	—	—	21.3% +9.35

Aug 13

LENSAR, Inc. has shown impressive Q2 results, with 18% YoY revenue growth and record profitability, breaking out of a slump and violently beating expectations.
The company's recurring revenue is high margin and growing, and it owns a quarter of the market, giving it a strong competitive position and patient capital.
LENSAR's operating expenses are plummeting, allowing for hockey stick profits, and its balance sheet is turning around with bigger cash generation around the corner, making it an attractive investment opportunity.

Generated by AI

Topics

Of the messages about LNSR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	69.84%
Technical Analysis	—	—	—	3.53%
Analysts	—	—	—	4.08%
Earnings	—	—	—	11.96%
Controversies	—	—	—	10.05%
Macro	—	—	—	0.54%

Mar 24

Alcon has agreed to acquire LENSAR, Inc. ($LNSR) for $14.00 per share in cash, with an additional $2.75 per share contingent on certain milestones.
The merger is subject to shareholder approval and is expected to be worth up to $430 million.
LENSAR shareholders are advised to vote against the deal, as the offer is considered grossly undervalued.

Generated by AI

Community

Of the messages about LNSR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	32.94%
Newcomers	—	—	—	67.06%

Aug 13

LENSAR, Inc. (LNSR) reported Q2 2026 earnings with a 18% YoY revenue growth and record profitability, with recurring revenue accounting for 83% of total revenue.
The company's Q2 results showed a significant improvement in its financial performance, with a net income of $3.5M and an Adjusted EBITDA of $3.6M, compared to a loss of $1.8M in the same period last year.
LENSAR's Q2 2026 earnings were seen as a positive surprise, with the stock surging 28% after the report, and the company's chart becoming one of the most interesting on the screen, according to market participants.

Generated by AI

LENSAR

Social

Aug 13

Aug 13

Mar 24

Aug 13

Lake Street Keeps Their Buy Rating on LENSAR (LNSR)

Lensar Inc Earnings Call Highlights Growth Momentum

LENSAR (LNSR) Q2 2026 Earnings Call Transcript

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge

Why is LENSAR stock surging today?

Also Discussed

LENSAR Inc.

Company Information

Location

Lake Street Keeps Their Buy Rating on LENSAR (LNSR)

Lensar Inc Earnings Call Highlights Growth Momentum

LENSAR (LNSR) Q2 2026 Earnings Call Transcript

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge

Why is LENSAR stock surging today?

Also Discussed

Social

Aug 13

Aug 13

Mar 24

Aug 13